Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Nektar Therapeutics shares valued at $23,400 were sold by CHESS ROBERT on Jun 14 ’24. At $1.20 per share, CHESS ROBERT sold 19,500 shares. The insider’s holdings dropped to 255,273 shares worth approximately $0.34 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, ROBIN HOWARD W sold 16,650 shares, netting a total of over 29,138 in proceeds. Following the sale of shares at $1.75 each, the insider now holds 863,239 shares.
Before that, Zalevsky Jonathan had sold 7,355 shares from its account. In a trade valued at $12,871, the Chief R&D Officer traded Nektar Therapeutics shares for $1.75 each. Upon closing the transaction, the insider’s holdings decreased to 7,355 shares, worth approximately $0.35 million.
As published in their initiating research note from Rodman & Renshaw on June 28, 2024, Nektar Therapeutics [NKTR] has been a Buy and the price target has been revised to $2. As of November 09, 2023, TD Cowen has increased its “Market perform” rating to a “an Outperform” for NKTR. Earlier on May 10, 2023, Jefferies upgraded its rating. Their new recommendation was “a Hold” for NKTR stock which previously was a “an Underperform”.
Analyzing NKTR Stock Performance
During the last five days, there has been a drop of approximately -4.96%. Over the course of the year, Nektar Therapeutics shares have jumped approximately 137.17%. Shares of the company reached a 52-week high of $1.9280 on 05/13/24 and a 52-week low of $0.4800 on 01/18/24. A 50-day SMA is recorded $1.3408, while a 200-day SMA reached $0.9394. Nevertheless, trading volume fell to 0.77 million shares from 0.98 million shares the previous day.
Support And Resistance Levels for Nektar Therapeutics (NKTR)
According to the 24-hour chart, there is a support level at 1.3033, which, if violated, would cause prices to drop to 1.2667. In the upper region, resistance lies at 1.3933. The next price resistance is at 1.4467. RSI (Relative Strength Index) is 48.79 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0417, which suggests the price will decrease in the coming days. Percent R is at 82.15%, indicating bearish price movement. Stochastics%K at holding indicates that the stock is to be held.
